Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01570556
Recruitment Status : Unknown
Verified March 2012 by Assaf-Harofeh Medical Center.
Recruitment status was:  Recruiting
First Posted : April 4, 2012
Last Update Posted : April 4, 2012
Information provided by (Responsible Party):
Assaf-Harofeh Medical Center

Brief Summary:
When considering occult infections during the diagnostic workup of inflammation in Hemodialysis (HD) patients, the urine-deprived bladder is frequently dismissed as potential site of infection. The urinary tract, even in end stage renal disease (ESRD) patients on hemodialysis may represent a significant reservoir for infection. Delayed diagnosis is a relevant issue because the urinary tract is often overlooked as a source of infection in dialysis patients, especially because of absence of urinary tract infection (UTI) symptoms in HD patients. Contributing factors to asymptomatic UTI in HD patients include the presence of low urine volume, bladder stasis, and the fact that UTI symptoms are mostly related to voiding, which is reduced or absent in these patients. Persistence of asymptomatic bacteriuria and UTI may be related to higher levels of inflammatory markers in HD population. In view of the association between cardiovascular disease and cardio-vascular and all-cause mortality with inflammation, as expressed by elevated CRP and/or IL-6 levels in HD patients, the investigators questioned whether presence of asymptomatic UTI could contribute to elevated levels of inflammatory markers in patients with ESRD on maintenance HD therapy. Such a finding would provide a potential link between a treatable infection and a potential cardiovascular risk factor in this population.

Condition or disease Intervention/treatment Phase
Inflammation on Dialysis Bacteriuria in Hemodialysis Patients Other: Antibiotic treatment Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients
Study Start Date : December 2011
Estimated Primary Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics Dialysis

Arm Intervention/treatment
Active Comparator: Patients with positive culture, treatment group
These asymptomatic patients with positive urinary culture, seven days of antibiotics will be given according to the bacteriogram sensitivity.
Other: Antibiotic treatment
In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.

No Intervention: Patients with positive culture, observation only
These asymptomatic patients with positive urine culture, will be observed only during the study period.

Primary Outcome Measures :
  1. Change in serum inflammatory markers (CRP, IL-6) [ Time Frame: 3 months, 6 months, and 12 months ]

Secondary Outcome Measures :
  1. Cardio-vascular events [ Time Frame: 3 months, 6 months and 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female, age > 18 years, in chronic hemodialysis treatment at least 3 months
  2. Stable and adequate hemodialysis treatment three months prior to participation in study as defined by Kt/V > 1.2 and hemodialysis performed at least 3 times weekly
  3. Patients with native A-V Fistula or graft
  4. Informed consent obtained before any trial-related activities

Exclusion Criteria:

  1. Patients with an indwelling catheters
  2. Patients with periodontitis
  3. Patients with diabetic foot
  4. Patients with active malignant disease or liver cirrhosis
  5. Patients on chronic treatment with steroids on doses > 10 mg/day Prednisone (or equivalent)
  6. Patients treated with immunosuppressive agents
  7. Patients suffering from

    • Acute vasculitis
    • Severe systemic infections
    • Heart failure (NYHA class III-IV)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01570556

Layout table for location information
Nephrology Department, Assaf Harofeh Medical Center Recruiting
Zerifin, Israel, 70300
Contact: Ilia Beberashvili, MD    972577346133   
Contact: Kobi Stav, MD    972527493007   
Principal Investigator: Ilia Beberashvili, MD         
Sponsors and Collaborators
Assaf-Harofeh Medical Center

Layout table for additonal information
Responsible Party: Assaf-Harofeh Medical Center Identifier: NCT01570556    
Other Study ID Numbers: 193/11
First Posted: April 4, 2012    Key Record Dates
Last Update Posted: April 4, 2012
Last Verified: March 2012
Keywords provided by Assaf-Harofeh Medical Center:
Interleukin 6
C reactive protein
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Urinary Tract Infections
Urologic Diseases
Anti-Bacterial Agents
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents